The Institute Mechnikov reports the successful prequalification of the "Flu-M" vaccine
The Latin American Biotechnology Institute Mechnikov in Nicaragua has achieved a significant international success: the "Flu-M" flu vaccine, produced in collaboration with the St. Petersburg Institute of Vaccines and Sera (IICVSSP) of Russia's FMBA, has successfully passed the prequalification process by the World Health Organization (WHO). This makes "Flu-M" the first flu vaccine from Central America officially recognized by the WHO and recommended for purchase by international agencies such as UNICEF and the Pan American Health Organization (PAHO).
"Flu-M" is a trivalent, inactivated, and split vaccine produced using a unique technology. Its advantage lies in the high level of antigen purification, reducing the ovalbumin content (the main allergen) to 1,000 times lower than in similar products. This minimizes the risk of allergic reactions and confirms the vaccine’s high quality.
The WHO prequalification status is the result of a thorough evaluation of the vaccine’s quality, safety, and efficacy, as well as an inspection of GMP-certified manufacturing facilities in both Russia and Nicaragua. The inclusion of "Flu-M" in the WHO’s list of recommended vaccines enables the manufacturer to expedite the registration process in other countries and access international markets.
The Institute Mechnikov, as the only facility in Central America dedicated to the final stages of production of sterile immunobiological products, plays a key role in strengthening the position of Russian pharmaceuticals in Latin America. In the region, only two flu vaccines have attained the WHO prequalification status, and "Flu-M" is one of them. This opens new opportunities for the institute, including expanded supplies through international organizations and strengthened partnerships with pharmaceutical stakeholders in the region.
The Institute Mechnikov’s product line includes the vaccines "Flu-M", "Flu-M Tetra", COVID-19 medications, and several new developments currently in the implementation phase. Since its founding in 2019, the total volume of supplies has exceeded 28 million doses. These achievements underscore the importance of the Institute Mechnikov's role in ensuring the global supply of accessible, high-quality vaccines.